CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
2.11
3.65%
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024318 %
Charges from full value of position ($-4.62)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024318%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002096 %
Charges from full value of position ($0.40)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002096%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 2.19
Open 2.15
1-Year Change -64.64%
Day's Range 2.07 - 2.17
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 10, 2024 2.19 -0.12 -5.19% 2.31 2.31 2.17
Dec 9, 2024 2.29 0.00 0.00% 2.29 2.47 2.28
Dec 6, 2024 2.13 -0.09 -4.05% 2.22 2.22 2.04
Dec 5, 2024 2.17 0.01 0.46% 2.16 2.17 1.98
Dec 4, 2024 2.16 -0.18 -7.69% 2.34 2.39 2.12
Dec 3, 2024 2.50 0.05 2.04% 2.45 2.55 2.44
Dec 2, 2024 2.48 -0.06 -2.36% 2.54 2.60 2.41
Nov 29, 2024 2.58 0.06 2.38% 2.52 2.66 2.38
Nov 27, 2024 2.52 -0.05 -1.95% 2.57 2.60 2.43
Nov 26, 2024 2.55 -0.06 -2.30% 2.61 2.67 2.35
Nov 25, 2024 3.94 -0.03 -0.76% 3.97 4.15 3.92
Nov 22, 2024 3.92 0.14 3.70% 3.78 4.08 3.74
Nov 21, 2024 3.74 0.11 3.03% 3.63 3.77 3.46
Nov 20, 2024 3.61 -0.17 -4.50% 3.78 3.82 3.58
Nov 19, 2024 3.82 0.14 3.80% 3.68 3.82 3.55
Nov 18, 2024 3.74 -0.39 -9.44% 4.13 4.13 3.67
Nov 15, 2024 4.04 -0.94 -18.88% 4.98 4.99 4.02
Nov 14, 2024 4.89 -0.23 -4.49% 5.12 5.13 4.87
Nov 13, 2024 5.10 -0.49 -8.77% 5.59 5.66 5.10
Nov 12, 2024 5.52 -0.39 -6.60% 5.91 6.02 5.43

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Alector, Inc. Company profile

About Alector Inc

Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The Company has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Alector Inc revenues increased from $21.1M to $207.1M. Net loss decreased 81% to $36.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative - Balancing decrease of 19% to $35.7M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.45 to -$0.45.

Industry: Bio Therapeutic Drugs

131 Oyster Point Blvd., Suite 600
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People also watch

BTC/USD

101,333.25 Price
+4.650% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

ETH/USD

3,815.58 Price
+4.790% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,720.02 Price
+0.920% 1D Chg, %
Long position overnight fee -0.0167%
Short position overnight fee 0.0085%
Overnight fee time 22:00 (UTC)
Spread 0.30

Oil - Crude

70.15 Price
+2.730% 1D Chg, %
Long position overnight fee 0.0069%
Short position overnight fee -0.0288%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading